Alina Galliano Pardo, MD
Psychiatry · Jacksonville, FLNPI 1073540993
Payments from drug & device makers
Across 294 payments — averaging $112.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Idorsia Pharmaceuticals US Inc$20K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$6K
- AbbVie$2K
- Johnson & Johnson$1K
- Brainsway USA Inc$785
- Otsuka America Pharmaceutical, Inc.$684
- plus $3K from 18 others
What the payments were for
- Consulting fees$3,52011%
- Speaking & faculty fees$18,57356%
- Travel & lodging$2,4037%
- Food & beverage$8,21525%
- Education$2501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Idorsia Pharmaceuticals US Inc | 31 | $20,055 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $5,544 |
| AbbVie(2 entities) | 122 | $1,889 |
| Johnson & Johnson | 31 | $1,188 |
| Brainsway USA Inc | 1 | $785 |
| Otsuka America Pharmaceutical, Inc. | 12 | $684 |
| Axsome Therapeutics, Inc. | 9 | $622 |
| Alkermes, Inc. | 8 | $471 |
| Teva Pharmaceuticals USA, Inc. | 11 | $357 |
| Ironshore Pharmaceuticals Inc. | 2 | $192 |
| Sunovion Pharmaceuticals Inc. | 3 | $167 |
| E.r. Squibb & Sons, L.L.C. | 3 | $158 |
| Braeburn Inc. | 2 | $147 |
| Tris Pharma Inc | 2 | $132 |
| Supernus Pharmaceuticals, Inc. | 5 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
| Corium, LLC | 3 | $75 |
| Vanda Pharmaceuticals Inc. | 4 | $71 |
| Indivior Inc. | 3 | $59 |
| Lundbeck LLC | 3 | $53 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $50 |
| Inspire Medical Systems, Inc. | 1 | $41 |
| Noven Therapeutics, LLC | 2 | $37 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QUVIVIQ$19,786
- CAPLYTA$4,957
- Deep TMS System$785
- SPRAVATO$779
- VRAYLAR$460
- REXULTI$441
- ARISTADA$413
- LYBALVI$408
- Auvelity$352
- Jornay PM 20mg capsules (Bottle of 100)$166
- ABILIFY MAINTENA$143
- ABILIFY ASIMTUFII$143
- VIVITROL$125
- LATUDA$125
- BRIXADI$122
- COBENFY$120
- Dyanavel XR$107
- ARISTADA INITIO$103
How this compares
$32,961 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 100 | $146,045 |
| Austedo XrDeutetrabenazine | 13 | $129,014 |
| VraylarCariprazine Hcl | 20 | $30,383 |
| CaplytaLumateperone Tosylate | 13 | $25,146 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $23,127 |
| QuviviqDaridorexant Hcl | 22 | $11,510 |
| Vilazodone Hcl | 25 | $4,178 |
| Quetiapine Fumarate | 77 | $2,229 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 32 | $1,744 |
| Lamotrigine | 69 | $1,336 |
| Clonazepam | 133 | $1,272 |
| Buspirone Hcl | 31 | $1,261 |
| Bupropion XlBupropion Hcl | 42 | $1,155 |
| Divalproex Sodium ErDivalproex Sodium | 23 | $996 |
| Eszopiclone | 41 | $795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $1,188 | $146,045100 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $357 | $129,01413 claims |
| AbbVieVraylar | $1,889 | $30,38320 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $5,544 | $25,14613 claims |
| Alkermes, Inc.Lybalvi | $471 | $23,12715 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $20,055 | $11,51022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Jacksonville
- John JoyceJacksonville$13.6M
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.